Sex differences and its impact on treatment outcomes of advanced melanoma in Germany – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG
Anna‐Sophia Leven(Essen University Hospital), Selma Ugurel(Klinikum Bielefeld), Patrick Terheyden(University Hospital Schleswig-Holstein), Jochen Utikal(German Cancer Research Center), Dirk Debus(Nuremberg Hospital), Rudolf Herbst(Helios Klinikum Erfurt), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Christoffer Gebhardt(Universität Hamburg), Michael Weichenthal(Christian-Albrechts-Universität zu Kiel), Claudia Pföhler(Saarland University), Sebastian Haferkamp(University Hospital Regensburg), Alexander Roesch(Essen University Hospital), Luisa Sophie Rajcsanyi(University of Duisburg-Essen), Dirk Schadendorf(National Center for Tumor Diseases), Friedegund Meier(National Center for Tumor Diseases), Jan‐Malte Placke(Düsseldorf University Hospital), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Stephan Grabbe(Goethe University Frankfurt), Alpaslan Tasdogan(Düsseldorf University Hospital), Elisabeth Livingstone(German Cancer Research Center), T. J. Peters(University Of Bristol Dental Hospital), Lisa Zimmer(The University of Sydney), Jessica C. Hassel(German Cancer Research Center), Alexander Kreuter(HELIOS St. Elisabeth Klinik Oberhausen), Ulrike Leiter(University of Tübingen), Carsten Weishaupt(University Hospital Münster), Imke von Wasielewski(Medizinische Hochschule Hannover), Anke Hinney(Philipps University of Marburg)
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k